Researchers have used a membrane-localizing technology to generate a novel class of thrombin inhibitors, named thrombalexins (TLNs), that bind to cell surfaces and could potentially be used to prevent acute antibody-mediated thrombosis in donor organs. In a rat renal allograft model of hyperacute antibody-mediated rejection, perfusion of donor kidneys with TLN-1 before transplantation substantially reduced intragraft thrombosis and increased graft survival.